Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Higher AML, MDS risk linked to autotransplants

Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Key clinical point: Autotransplant for lymphoma or plasma cell myeloma is a strong risk factor for AML and myelodysplastic syndrome.

Major finding: Patients undergoing autologous hematopoietic cell transplantation have risks for AML and MDS that are 10-100 times higher than those of the general population.

Study details: A retrospective cohort study of 9,028 patients undergoing hematopoietic cell autotransplant during 1995-2010 for Hodgkin lymphoma, non-Hodgkin lymphoma, or plasma cell myeloma.

Disclosures: The Center for International Blood and Marrow Transplant Research is supported by U.S. government agencies and numerous pharmaceutical companies. The authors reported that they have no relevant conflicts of interest.

Read the article.


Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Must Reads in Aggressive Lymphomas

Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025